About Genomic Health: Genomic Health, Inc. is a global cancer company focused on the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its lead product, the Oncotype DX® breast cancer test, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer and has been shown to the predict the likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to this widely adopted test, Genomic Health provides the Oncotype DX colon cancer test, the first multigame expression test developed for the assessment of risk of recurrence in patients with stage II disease. As of December 31, 2011 , more than 10,000 physicians in over 65 countries had ordered more than 265,000 Oncotype DX tests. Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional treatment decisions in breast and colon cancers. The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.
"To drive major improvements, performance-based payments must exceed 10% of total provider income. Incentives of this magnitude can only be mobilized if they originate in payer savings.”
Arnold Milstein, MD, MPH,
Other IHA partnerships:
University of California Berkeley Center for Health Technology (BCHT) BCHT conducts research into existing and improved criteria for coverage, consumer cost-sharing, and other dimensions of management for biomedical innovations, and provides academic programs for UC Berkeley graduate students and professional development for health care organizations.
California Center for Public Health Advocacy, a nonpartisan nonprofit organizations that raises awareness about critical public health issues and mobilizes communities to promote the establishment of effective state and local health policies.